Effective drug delivery is a cornerstone of preclinical research across multiple modalities, serving as the crucial link between emerging therapeutic candidates and potential clinical applications. MuriPhys harnesses specialized technology, proprietary techniques, and extensive experience in preclinical development to deliver exceptional precision and quality. By prioritizing robust methodologies and reproducible outcomes, MuriPhys supports each study saves its partners valuable time and resources, speeding the path from discovery to successful clinical translation.
MuriPhys supports multiple CNS delivery routes for rodent preclinical studies, allowing sponsors to match the route of administration to the therapeutic modality, target anatomy, and study objective.
MuriPhys excels at tailoring preclinical drug delivery strategies to meet diverse sponsor needs, whether it’s viral-based gene therapy or cell transplant therapies. By combining specialized technologies, deep scientific expertise, and flexible operational protocols, MuriPhys supports each program benefits from meticulously customized methods. Below are some key product and delivery platforms that define MuriPhys’ comprehensive capabilities:
Drug Products
-
Therapeutic Modalities (Gene Therapy, Gene Editing, ASOs, siRNAs) - MuriPhys provides precise, targeted delivery for a range of therapeutic modalities. Our team has extensive hands-on experience with vector engineering, dose optimization, and tissue-specific administration, supporting the highest possible efficacy and safety profiles for gene therapy and editing applications. Proprietary formulations and rigorous quality checks further enhance the reliability of ASOs and siRNAs in preclinical studies.
-
Small Molecules / Biologics - For traditional small molecule compounds and complex biologics, MuriPhys leverages advanced delivery techniques and detailed pharmacokinetic assessments. Our robust protocols maximize bioavailability and therapeutic impact while maintaining strict control over dosing schedules. This disciplined approach helps sponsors swiftly generate meaningful, reproducible data.
-
Nanoparticles - MuriPhys offers specialized expertise in nanoparticle-based delivery systems, including liposomes, polymeric carriers, and lipid nanoparticles (LNPs).
-
Monoclonal Antibodies (mAbs) - Leveraging decades of combined immunology and preclinical research experience, MuriPhys refines administration protocols for monoclonal antibodies to improve binding, distribution, and therapeutic window. We emphasize assay development, immune response profiling, and PK/PD correlation, delivering actionable data that can inform both safety and efficacy endpoints.
-
Cell Transplants - Our dedicated cell biology team guides sponsors through every stage of cellular therapy programs, including donor cell sourcing, expansion, and transplantation. Meticulous handling and defined SOPs for injection routes and follow-up testing reduce variability, supporting each cell transplant study yields reliable, translational results.
By seamlessly integrating these platforms into a single preclinical framework, MuriPhys delivers consistent, high-quality data that shortens development timelines and reduces costs. Our commitment to rigorous research standards, flexible study designs, and transparent communication empowers sponsors to navigate the drug development pathway with confidence and efficiency.
